2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
105
Carcinoma, Renal Cell
38
Leukemia, Myeloid, Acute
36
Neoplasm Metastasis
31
Neoplasms
22
Breast Neoplasms
22
Lymphoma, Non-Hodgkin
21
Kidney Neoplasms
20
Leukemia
18
Carcinoma, Non-Small-Cell Lung
18
Skin Neoplasms
17
Neuroblastoma
17
Ovarian Neoplasms
16
Colorectal Neoplasms
16
Recurrence
14
Leukemia, Lymphocytic, Chronic, B-Cell
14
Lymphoma
13
Myelodysplastic Syndromes
10
Uveal Melanoma
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, Follicular
9
Head and Neck Neoplasms
9
Uterine Cervical Neoplasms
8
Multiple Myeloma
8
Congenital Abnormalities
8
Triple Negative Breast Neoplasms
7
Stomach Neoplasms
7
Lung Neoplasms
7
Hodgkin Disease
7
Squamous Cell Carcinoma of Head and Neck
6
Interventions
pembrolizumab
10
Nivolumab
9
Ipilimumab
4
avelumab
3
Neoadjuvant Therapy
3
toripalimab
2
sintilimab
2
durvalumab
2
atezolizumab
2
Specimen Handling
2
Immune Checkpoint Inhibitors
2
Celecoxib
2
tislelizumab
1
spartalizumab
1
relatlimab
1
regorafenib
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
denileukin diftitox
1
danvatirsen
1
camrelizumab
1
XELOX
1
Taxes
1
Surgical Procedures, Operative
1
Radiation Dose Hypofractionation
1
Paclitaxel
1
Oxaliplatin
1
Megestrol Acetate
1
Medroxyprogesterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Turcot syndrome
×
Interleukin-2
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled